New pivotal trial needed for Vion's leukaemia drug Onrigin
This article was originally published in Scrip
Executive Summary
A new Phase III trial of Vion Pharmaceuticals' lead oncology drug candidate Onrigin (laromustine; formerly cloretazine) in acute myeloid leukaemia (AML) will be needed after the US FDA told the company that an ongoing, independently sponsored Phase III trial would not suffice for the chemotherapy drug's approval.